正文
Antibody Therapeutics
, Volume 2, Issue 4, October 2019, Pages 79–87
https://doi.org/10.1093/abt/tbz010
[3] Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society
Hongyu Zhang, Mi Deng, Fen Pei, Shouye Wang, Mitchell Ho
Antibody Therapeutics
, Volume 2, Issue 4, October 2019, Pages 99–107
https://doi.org/10.1093/abt/tbz012
[4] Biology drives the discovery of bispecific antibodies as innovative therapeutics
Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu, Jijie Gu
Antibody Therapeutics
, Volume 3, Issue 1, January 2020, Pages 18–62
https://doi.org/10.1093/abt/tbaa003
[5] Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications
Yong Zhu, Run Shen, Rui Hao, Shouye Wang, Mitchell Ho
Antibody Therapeutics
, Volume 3, Issue 2, April 2020, Pages 146–154
https://doi.org/10.1093/abt/tbaa012
[6] Development of bispecific antibodies in China: overview and prospects
Jing Zhang, Jizu Yi, Pengfei Zhou
Antibody Therapeutics
, Volume 3, Issue 2, April 2020, Pages 126–145
https://doi.org/10.1093/abt/tbaa011
[7] Current trends and challenges in the downstream purification of bispecific antibodies
Serene W Chen, Wei Zhang
Antibody Therapeutics
, Volume 4, Issue 2, April 2021, Pages 73–88
https://doi.org/10.1093/abt/tbab007
[8] An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
Ninghai Wang, Harshal Patel, Irene C Schneider, Xin Kai, Avanish K Varshney, Li Zhou
Antibody Therapeutics
, Volume 4, Issue 2, April 2021, Pages 90–100
https://doi.org/10.1093/abt/tbab009
[9] Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
Hui Xiong, Fengyan Luo, Pengfei Zhou, Jizu Yi
Antibody Therapeutics
, Volume 4, Issue 4, October 2021, Pages 212–221
https://doi.org/10.1093/abt/tbab022
[10] Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
Wenyan Cai, Jianbo Dong, Sachith Gallolu Kankanamalage, Allison Titong, Jiadong Shi, Zhejun Jia, Bo Wang, Cai Huang, Jing Zhang, Jun Lin,
Steven Z Kan, Shuhua Han, Joe Zhou, Yue Liu
Antibody Therapeutics
, Volume 4, Issue 4, October 2021, Pages 228–241
https://doi.org/10.1093/abt/tbab024
[11] Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture
Yongjun Qin, Rongmei Ma, Yang Li, Yifeng Li, Gong Chen, Weichang Zhou
Antibody Therapeutics
, Volume 5, Issue 2, April 2022, Pages 111–120
https://doi.org/10.1093/abt/tbac009
[12] Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
